RNA interference in cancer
- PMID: 16466964
- DOI: 10.1016/j.bioeng.2006.01.002
RNA interference in cancer
Abstract
In the recent years, RNA interference (RNAi) has emerged as a major regulatory mechanism in eukaryotic gene expression. The realization that changes in the levels of microRNAs are directly associated with cancer led to the recognition of a new class of tumor suppressors and oncogenes. Moreover, RNAi has been turned into a potent tool for artificially modulating gene expression through the introduction of short interfering RNAs. A plethora of individual inhibitory RNAs as well as several large collections of these reagents have been generated. The systems for stable and regulated expression of these molecules emerged as well. These tools have helped to delineate the roles of various cellular factors in oncogenesis and tumor suppression and laid the foundation for new approaches in gene discovery. Furthermore, successful inhibition of tumor cell growth by RNAi aimed at oncogenes in vitro and in vivo supports the enthusiasm for potential therapeutic applications of this technique. In this article we review the evidence of microRNA involvement in cancer, the use of short interfering RNAs in forward and reverse genetics of this disease, and as well as both the benefits and limitations of experimental RNAi.
Similar articles
-
[RNA interference (RNAi) and its therapeutic potential in cancer].Rev Invest Clin. 2010 Jan-Feb;62(1):81-90. Rev Invest Clin. 2010. PMID: 20415062 Review. Spanish.
-
RNA interference for the treatment of cancer.Drug News Perspect. 2006 Jul-Aug;19(6):317-24. doi: 10.1358/dnp.2006.19.6.985937. Drug News Perspect. 2006. PMID: 16971967 Review.
-
Short interfering RNAs as a tool for cancer gene therapy.Cancer Gene Ther. 2005 Mar;12(3):217-27. doi: 10.1038/sj.cgt.7700791. Cancer Gene Ther. 2005. PMID: 15550938 Review.
-
Prospects of RNA interference therapy for cancer.Gene Ther. 2006 Mar;13(6):464-77. doi: 10.1038/sj.gt.3302694. Gene Ther. 2006. PMID: 16341059 Review.
-
RNA interference as potential therapy for neurodegenerative disease: applications to inclusion-body myositis?Neurology. 2006 Jan 24;66(2 Suppl 1):S114-7. doi: 10.1212/01.wnl.0000192310.07041.53. Neurology. 2006. PMID: 16432138 Review.
Cited by
-
Silencing VP28 gene of white spot syndrome virus of shrimp by bacterially expressed dsRNA.Mar Biotechnol (NY). 2008 Mar-Apr;10(2):198-206. doi: 10.1007/s10126-007-9052-y. Epub 2007 Oct 27. Mar Biotechnol (NY). 2008. PMID: 17965920
-
The role of polo-like kinase 3 in the response of BRAF-mutant cells to targeted anticancer therapies.Mol Carcinog. 2020 Jan;59(1):5-14. doi: 10.1002/mc.23123. Epub 2019 Sep 30. Mol Carcinog. 2020. PMID: 31571292 Free PMC article.
-
Tsetse salivary gland hypertrophy virus: hope or hindrance for tsetse control?PLoS Negl Trop Dis. 2011 Aug;5(8):e1220. doi: 10.1371/journal.pntd.0001220. Epub 2011 Aug 30. PLoS Negl Trop Dis. 2011. PMID: 21912708 Free PMC article. Review.
-
Reduced high-mobility group box 1 expression induced by RNA interference inhibits the bioactivity of hepatocellular carcinoma cell line HCCLM3.Dig Dis Sci. 2012 Jan;57(1):92-8. doi: 10.1007/s10620-011-1944-z. Epub 2011 Oct 26. Dig Dis Sci. 2012. PMID: 22038506
-
Silencing of signal transducer and activator of transcription 3 expression by RNA interference suppresses growth of human hepatocellular carcinoma in tumor-bearing nude mice.World J Gastroenterol. 2009 Jun 7;15(21):2602-8. doi: 10.3748/wjg.15.2602. World J Gastroenterol. 2009. PMID: 19496189 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical